SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6]
16 references·1 citing·38 second hop
Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6] (2018)Review of Recent US Value Frameworks—A He…Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Defining Elements of Value in…Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5] (2018)Approaches to Aggregation and…A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7] (2018)A Health Economics Approach t…A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1] (2018)A Health Economics Approach t…Using Cost-Effectiveness Analysis to Address Health Equity Concerns (2017)Using Cost-Effectiveness Anal…Cost Effectiveness in Health and Medicine (2017)Cost Effectiveness in Health …Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)Updating the American Society…The Limitations of QALY: A Literature Review (2016)The Limitations of QALY: A Li…Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial (2016)Extended Cost-Effectiveness A…Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research (2016)Country-Level Cost-Effectiven…Cost-Effectiveness in Health and Medicine (2016)Cost-Effectiveness in Health …Measuring the Value of Prescription Drugs (2015)Measuring the Value of Prescr…American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)American Society of Clinical …A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)A standardised, generic, vali…Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Updating Cost-Effectiveness —…The NICE Cost-Effectiveness Threshold (2008)The NICE Cost-Effectiveness T…What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks (2021)What Is Value in Health and H…Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)GRADE guidelines: 3. Rating the quality of evidence (2011)Economic burden of cancer across the European Union: a population-based cost analysis (2013)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Net Health Benefits (1998)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)Essential medicines for universal health coverage (2016)Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World (2003)Methods for the Economic Evaluation of Health Care Programmes (2005)The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought (2016)The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion (2020)Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures (2023)Cost-Effectiveness in Health and Medicine (1996)World Development indicators (2015)Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report (2018)Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA (2018)An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations (2021)Closing the gap in a generation: health equity through action on the social determinants of health (2008)WHO European review of social determinants of health and the health divide (2012)Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR (2018)Distributional Cost-Effectiveness Analysis Comes of Age (2020)Hedonic Prices and Implicit Markets: Product Differentiation in Pure Competition (1974)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2] (2018)The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) (2023)Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)The cost-effectiveness of digital health interventions: A systematic review of the literature (2022)On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review (2018)Economics and mental health: the current scenario (2020)A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors (2018)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)Medical Care Costs Associated with Cancer Survivorship in the United States (2020)Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report (2015)Simulating the Potential Impacts of COVID-19 School Closures on Schooling and Learning Outcomes: A Set of Global Estimates (2020)
this work references cited by second hop

References

  • 2014Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold2,247 cited
  • 2016Cost-Effectiveness in Health and Medicine1,550 cited
  • 2015American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options916 cited
  • 2016Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research889 cited
  • 2008The NICE Cost-Effectiveness Threshold868 cited
  • 2015A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)817 cited
  • 2016Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received655 cited
  • 2018Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]544 cited
  • 2017Using Cost-Effectiveness Analysis to Address Health Equity Concerns328 cited
  • 2016Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial251 cited
  • 2017Cost Effectiveness in Health and Medicine222 cited
  • 2018A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]152 cited
  • 2015Measuring the Value of Prescription Drugs144 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2018A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1]135 cited
  • 2016The Limitations of QALY: A Literature Review110 cited
  • 2018Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]91 cited
  • Cited by

    • 2021What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks55 cited